Unity Biotechnology has yet to demonstrate that its drugs can treat diseases of aging in humans but it now has $85 million to start tests.
The Brisbane, CA, drug developer priced its initial public offering of 5 million shares late Wednesday at $17 apiece. That price was the midpoint of the $16 to $18 range it had previously set. Shares are expected to begin trading Thursday on the Nasdaq exchange under the stock symbol “UBX.”
Unity aims to treat diseases of aging at the cellular level. The company is developing drugs that target senescent cells– dormant cells that still secrete… Read more »
UNDERWRITERS AND PARTNERS